Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

6-9 November, 2018
Postillion Convention Center,
Amsterdam, Netherlands

Increase half-life and minimise manufacturing costs through new data, case studies and technologies for peptide therapeutics

Accelerate your peptide therapeutics to market

Discovery & R&D
  • New frontiers in peptide therapeutics – Where are the future opportunities?
  • Explore the latest selection and screening technologies for lead discovery
  • Improve drug-like properties of next generation peptide therapeutics: Lead optimisation and engineering strategies
  • Implement cost of goods modelling to evaluate potential drug candidates
Delivery & Clinical Updates
  • What are the most exciting peptides advancing through the clinic?
  • Get top tips learnt from preclinical and clinical development
  • Examine the latest advances in oral peptide therapeutics
  • Stay on top of new techniques for improved administration of peptide products
Manufacturing & CMC
  • Delve into strategies to reduce cost of goods and improve manufacturing efficiency
  • Master process development and scale up of complex peptide therapeutics
  • Discover how enzymatic synthesis and continuous flow can be applied to large scale production
  • Uncover analytical methods to identify and characterise peptide impurities

NEW TOPICS AND INDUSTRY CASE STUDIES FOR 2018 FOCUSED ON:

  • Cost of Goods Modelling and Strategies to Evaluate Potential Drug Candidates
  • Enzymatic peptide synthesis
  • Non-Clinical Safety Assessment and Toxicology Programmes for Peptides
  • Large Scale Application of Continuous Manufacturing for Peptide Therapeutics
  •  Industry Applications of QbD and Risk Based Approaches for Peptide Therapeutics

GAIN THE SCIENCE, TECHNOLOGIES AND CONTACTS YOU NEED TO ACCELERATE PEPTIDE THERAPEUTICS TO MARKET

300+
OLIGONUCLEOTIDE AND PEPTIDE SCIENTISTS AND EXECUTIVES
40+
CASE STUDIES AND NEW DATA PRESENTATIONS
30+
LEADING EXHIBITORS

Thank you to our EuroPEPTIDES 2018 Scientific Advisory Board

  • Waleed Danho, Former, Distinguished Research Leader, Roche, USA
  • Bruce Morimoto, Executive Director, Applied Translational Medicine, Celerion, USA
  • Thomas Meier, Chief Operations Officer, Bachem Europe, Switzerland
  • Jesper Lau, Vice President, Diabetes Protein & Peptide Chemistry, Novo Nordisk, Denmark
  • Joel Richard, Senior Vice President, Peptides - Head of CMC Development, Ipsen, France
  • Neil Thompson, Director Business Development, PolyPeptide
  • Leila Malik, CMC Project Manager, Zealand Pharma
  • Michael Postlethwaite, Program and Business Development Manager, Bachem, Switzerland

PARTNERING OPPORTUNITIES AT EuroPEPTIDES 2018


Highlight your company's expertise to 300+ scientists and key decision makers working across peptide & oligonucleotide development.  A wide variety of options are available to accommodate your company's goals and budget.